成人弥漫性低级别胶质瘤替莫唑胺化疗的临床研究

发布时间：2018-06-15 20:04

本文选题：成人弥漫性低级别胶质瘤 + 无进展生存时间　；参考：《中国肿瘤临床》2016年17期

【摘要】：目的:比较成人弥漫性低级别胶质瘤患者手术加常规分割放疗后加替莫唑胺化疗(化疗组)和不加替莫唑胺化疗(对照组)的无进展生存时间(progression free survival time,PFS),明确化疗对于成人弥漫性低级别胶质瘤患者的治疗意义。方法:回顾性分析首都医科大学附属北京天坛医院神经外科于2005年5月至2008年4月收治的64例成人弥漫性低级别胶质瘤患者,其中对照组(46例)行手术后仅接受放疗,化疗组(18例)行手术和放疗后,接受替莫唑胺化疗4~12个周期,比较两组患者的PFS是否存在显著性差异。结果:化疗组的中位PFS为67.8个月,对照组的中位PFS为51.3个月。采用Kaplan-Meier生存分析的Log-rank法进行检验(χ~2=8.741,P=0.003),差异具有统计学意义。结论:成人弥漫性低级别胶质瘤患者接受替莫唑胺化疗能提高PFS。
[Abstract]:Objective: to compare the progression-free survival time (free survival) of gatimozolamide chemotherapy (chemotherapy group) and non-telmozolium chemotherapy (control group) in adult patients with diffuse low grade glioma after surgery and conventional fractionated radiotherapy, and to determine the chemotherapy. Clinical significance of treatment for diffuse low grade gliomas in adults. Methods: from May 2005 to April 2008, 64 patients with diffuse low grade glioma in Beijing Temple of Heaven Hospital affiliated to Capital Medical University were retrospectively analyzed. 46 patients in the control group were treated with radiotherapy only after operation. The patients in the chemotherapy group (n = 18) were treated with temozolidomide for 4 ~ 12 cycles after operation and radiotherapy. The PFS of the two groups was significantly different. Results: the median PFS was 67.8 months in chemotherapy group and 51.3 months in control group. Kaplan-Meier survival analysis was performed with Log-rank method (蠂 ~ 2 / 2 ~ (8.741) P ~ (0.003). The difference was statistically significant. Conclusion: temozolidomide chemotherapy can improve PFS in adult patients with diffuse low grade gliomas.
【作者单位】：首都医科大学附属北京天坛医院神经外科;
【基金】：北京市青年拔尖人才计划项目(编号:2015000021223ZK28)资助~~
【分类号】：R739.4

【相似文献】